<DOC>
	<DOCNO>NCT02492711</DOCNO>
	<brief_summary>The purpose study determine whether patient treat margetuximab plus chemotherapy long progression free survival overall survival patient treat trastuzumab plus chemotherapy .</brief_summary>
	<brief_title>Margetuximab Plus Chemotherapy v Trastuzumab Plus Chemotherapy Treatment HER2+ Metastatic Breast Cancer</brief_title>
	<detailed_description>An evaluation efficacy , measure progression-free survival ( PFS ) assess independent review overall survival ( OS ) , margetuximab plus chemotherapy compare trastuzumab plus chemotherapy patient advance HER2+ breast cancer receive prior treatment trastuzumab , pertuzumab , ado-trastuzumab emtansine neoadjuvant , adjuvant , metastatic setting , receive least one , three , line therapy metastatic setting .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Histologicallyproven metastatic locallyadvanced relapsed/refractory HER2+ breast cancer base recently available tumor biopsy collect patient . Tumors may estrogen receptor ( ER ) /progesterone receptor ( PR ) positive negative . Prior treatment pertuzumab , trastuzumab , adotrastuzumab emtansine neoadjuvant , adjuvant , metastatic setting . Prior radiotherapy , hormonal therapy , antiHER2 therapy allow . Prior treatment least one , three , line therapy metastatic setting . Patients must progress following , recent line therapy . Resolution chemotherapy radiationrelated toxicity ≤ Grade 1 Life expectancy ≥ 12 week Acceptable laboratory parameter Women childbearing potential must negative pregnancy test perform within 7 day randomization first day treatment . All subject must agree use effective form contraception duration study treatment 7 month last dose study drug Known , untreated brain metastasis . Patients sign symptom brain metastasis must CT MRI perform within 4 week prior randomization specifically exclude presence radiographicallydetected brain metastasis History uncontrolled seizure within 6 month randomization History prior allogeneic bone marrow , stemcell , solid organ transplantation History clinically significant cardiovascular disease Clinicallysignificant pulmonary compromise , include requirement supplemental oxygen use maintain adequate oxygenation Any condition would contraindication receive trastuzumab describe approve local label condition would prevent treatment physician 's choice chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>